$ABSI

Szela Mary T purchased $149K of ABSI

Szela Mary T purchased 12,900 shares of Absci Corp (ABSI) at $11.54 ($0.15M total) on 2026-06-30.

Original reporting
SEC EDGAR · Szela Mary T
Published Jul 6, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABSI
Bullish
low confidence
Mentioned
$ABSI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABSIBullishLow
01

Why it matters

The disclosure provides incremental sentiment information but does not change the company’s fundamentals on its own.

02

Market read

Traders may note the insider buy, but there is no new operational or financial catalyst in the text.

03

What to watch

No 10b5-1 plan and no stated rationale; also, the filing is dated after the purchase, reducing immediacy for traders.

Relevance 5/10Novelty 3/10Timing: New Form 4 filed 2026-07-06; reflects purchase dated 2026-06-30.

Background

The article is a SEC Form 4 insider transaction disclosure for Absci Corp.

Company-level read

Ticker impact

$ABSIBullishLow confidence
Context

Absci director Szela Mary T filed a Form 4 open-market purchase of 12,900 shares at $11.54 on 2026-06-30.

Expected impact

Likely limited near-term price impact; may modestly support sentiment rather than drive a repricing.

Evidence & confidence

This is a routine insider Form 4 purchase with no accompanying fundamental catalyst (no guidance, trial, deal, or regulatory action).

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary or tax/portfolio-driven and may not indicate near-term operational improvement.

Key entities

  • Absci Corp

    Subject of the Form 4 insider transaction disclosure.

  • Szela Mary T

    Director who purchased 12,900 shares open-market at $11.54 on 2026-06-30.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABSIMed

Absci (ABSI) Q2 2026 Earnings Call Transcript

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

$ABSIHighAI 9/10

Why is Absci stock tumbling today?

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

$ABSIMed

Absci Corp (ABSI): Results of Operations and Financial Condition

Absci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly

$ABSIMed

Absci (NASDAQ:ABSI) Shares Gap Up Following Analyst Upgrade

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.